PolyPeptide Reports Robust H1 2026 Growth and Updates Full-Year Outlook

PolyPeptide Group AG, a CDMO for peptide pharmaceuticals, reported a 42% revenue growth in H1 2026, reaching EUR 236.6 million. This increase was driven by a 72.7% surge in metabolic therapeutics. The company improved its EBITDA to EUR 49.1 million from EUR 4.4 million in H1 2025, aided by higher sales and the sale of intangible assets. However, investments in capacity expansion and staffing partially offset these gains.

PolyPeptide now anticipates a 25-30% revenue growth for 2026, upgrading its previous estimate of 20-25%. The EBITDA margin is expected to be in the high-teens. Operationally, the company advanced its global capacity expansions and maintained a strategic focus on technological innovations.

The company confirmed its 2028 mid-term outlook, aiming to double 2023 revenue and enhance profitability, targeting a 25% EBITDA margin.